2. U.S. Food and Drug Administration accepts Bristol Myers Squibb’s application for subcutaneous nivolumab (nivolumab and hyaluronidase). News Release. Bristol Myers Squibb. May 8, 2024.

The subcutaneous formulation also significantly reduced drug administration time (7.4 minutes vs. 61.6 minutes; P < .0001) and treatment experience time (96 minutes vs. 177.8 minutes; P < .0001).

Subcutaneous administration led to 8.1% of patients overall having local injection site reactions (15.3% in lecanemab-naive patients). Most were mild and moderate in severity consisting of redness ...

He also went on to add his thoughts on how this may impact treatment adherence and quality of life for patients receiving immunotherapy. Notably, this interview came following the Dec. 27, 2024, Food ...

The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up ...

Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today that a peer-reviewed study conducted by researchers at Stanford University and published in ...

However, in December 2024, the Food and Drug Administration (FDA) approved a new version of nivolumab (Opdivo Qvantig) for use as a subcutaneous injection. This means the drug can be injected ...

Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME ...

The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe ulcerative colitis following induction ...

This time-intensive IV administration could prove to be a competitive disadvantage in comparison to Ocrevus' newly confirmed 10-minute subcutaneous injections, given twice yearly.

There are many benefits to subcutaneous administration vs IV, McCreary said. “You don’t need to start an intravenous line, so you avoid the line kit and the nursing time needed for that.

Basel, 13 September 2024- Roche announced today that the U.S. Food and Drug Administration has approved Tecentriq Hybreza TM, the first and only PD- 1 inhibitor for subcutaneous, under the skin ...